Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2026-2034

The global adult malignant glioma therapeutics market size stood at USD 2.7 billion in 2025. The market is projected to grow from USD 2.96 billion in 2026 to USD 6.59 billion by the end of 2034, exhibiting a CAGR of 10.50% during the forecast period (2026-2034). North America dominated the adult malignant glioma therapeutics market with a market share of 48.20% in 2025.

Gliomas are a type of tumor that starts at glial cells of the brain and spine are the most common type of brain tumors. According to Atlas of Genetics and Cytogenetics in Oncology and Hematology, glioma comprises of about 30% of the brain tumors and 70% of all the malignant tumors. Glioblastoma multiforme (GBM) is the most aggressive and difficult to treat form of the disease with a median survival rate of 12 months.

The growing prevalence of the disease, huge unmet need, poor survival rate, and lack of effective therapies for the complete cure of the disease leverages great opportunity for the players to invest in the research and development of glioma therapies. Currently, available therapies prescribed for adult malignant glioma therapy include surgery, chemotherapy, radiation therapy, and targeted therapies among others.

Global Adult Malignant Glioma Therapeutics Market Overview

Market Size & Forecast:

• 2025 Market Size: USD 2.7 billion
• 2026 Market Size: USD 2.96 billion
• 2034 Forecast Market Size: USD 6.59 billion
• CAGR: 10.50% from 2026–2034

Market Share:

• North America dominated the adult malignant glioma therapeutics market with a 48.20% share in 2025, driven by high disease prevalence, robust healthcare infrastructure, significant healthcare spending, and advanced diagnostic capabilities.
• Targeted therapy is expected to emerge as the most attractive treatment type segment, projected to grow at the highest CAGR during the forecast period due to advancements in molecular targeting and improved survival outcomes for glioblastoma multiforme (GBM) patients.

Key Country Highlights:

• Japan: Growing focus on innovative therapies and government support for neuro-oncology research fuel market growth.
• United States: High incidence of malignant glioma (~17,000 new high-grade glioma cases in 2024), strong healthcare spending, supportive regulatory environment, and widespread awareness contribute to market dominance.
• China: Increasing investment in healthcare infrastructure and rising prevalence of brain tumors support market expansion.
• Europe: Advances in imaging technologies, reimbursement policies, and growing awareness about malignant gliomas drive steady market growth.

Market Dynamics

The adult malignant glioma therapeutics market share is anticipated to expand at a near two-digit CAGR during the forecast period attributable to supportive government and regulatory policies for the development of novel therapies, advancements in the imaging technologies resulting in early detection of the disease, and favorable reimbursement policies for the glioma products across many regions of the world.

Download Free sample to learn more about this report.

Segmentation Analysis

By Therapy Type

Targeted Therapy Segment to Expand at the Highest CAGR Owing to Advancements in Precision Oncology

Glioblastoma Multiforme (GBM), the most aggressive and recurrent form of adult malignant glioma, is primarily treated using first-line and second-line therapies. Conventionally, temozolomide combined with radiotherapy remains the standard first-line treatment approach, contributing 68% globally in 2026. However, disease recurrence is common, and once relapse occurs, therapeutic options become significantly limited.

Recent advances in drug development and molecular oncology have enabled the successful application of targeted therapies, which are increasingly being adopted to improve patient survival outcomes. Commonly used targeted therapies in glioma treatment include EGFR-targeted therapies and therapies targeting tyrosine kinase receptors. Owing to their ability to act on specific molecular pathways and reduce systemic toxicity, the targeted therapy segment is projected to expand at the highest CAGR during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Disease Type

Glioblastoma Multiforme Segment to Maintain Dominance Due to High Disease Prevalence and Poor Prognosis

In terms of disease type, the glioblastoma multiforme (GBM) segment held the largest share of the adult malignant glioma therapeutics market in 2024. GBM remains the most commonly diagnosed malignant glioma among adults and is characterized by rapid progression, high recurrence rates, and limited long-term survival.

The dominance of this segment is supported by high unmet medical need, increasing diagnosis rates, and continuous research efforts focused on improving treatment efficacy. The GBM segment is expected to retain its leading position throughout the forecast period, driven by sustained demand for innovative and advanced therapeutic options.

By End User

Hospitals Segment Leads Market, While Cancer & Radiation Therapy Centers Witness Faster Growth

Based on end user, the market is segmented into hospitals, cancer and radiation therapy centers, and others.

The hospitals segment accounted for the largest market share, supported by the availability of advanced diagnostic infrastructure, multidisciplinary treatment approaches, and access to standard and emerging therapies under one roof, accounting for 44.72% market share in 2026

However, the cancer and radiation therapy centers segment is projected to expand at the highest CAGR during the forecast period, with a share of 48.5% in 2026. This growth is attributed to the availability of specialized oncology care, increasing patient preference for dedicated cancer treatment facilities, and the rising adoption of advanced radiation and targeted therapy protocols tailored specifically for malignant glioma management.

Regional Analysis

North America

To get more information on the regional analysis of this market, Download Free sample

The North America held the dominant share in 2026 valuing at USD 1.43 Billion and also took the leading share in 2025 with USD 1.3 Billion. North America dominates the adult malignant glioma therapeutics market, driven by the rising incidence of glioblastoma multiforme (GBM) and advanced diagnostic capabilities. According to the American Society of Clinical Oncology, about 17,000 new cases of high-grade gliomas (HGG) are expected to be diagnosed in the United States in 2024. Strong economic conditions, high healthcare spending, widespread awareness, and early diagnosis rates, along with active clinical trials and rapid adoption of novel therapeutics in the U.S. and Canada, continue to support regional dominance. The U.S. market is projected to reach USD 1.29 billion by 2026.

Europe

Europe represents a significant share of the adult malignant glioma therapeutics market, supported by well-established neuro-oncology treatment frameworks and strong public healthcare systems across countries such as Germany, France, the U.K., Italy, and Spain. The region benefits from high diagnosis rates, increasing use of advanced radiotherapy and combination drug regimens, and strong collaboration between academic research centers and pharmaceutical companies. The UK market is projected to reach USD 0.18 billion by 2026, while the Germany market is projected to reach USD 0.27 billion by 2026.

Asia Pacific

Asia Pacific is expected to witness steady growth over the forecast period due to improving diagnostic infrastructure and increasing awareness of malignant brain tumors in developing economies including China and India. Expansion of tertiary healthcare facilities, rising healthcare investments, and gradual uptake of advanced therapeutics in Japan, South Korea, and Australia are further contributing to market expansion in the region. The Japan market is projected to reach USD 0.07 billion by 2026, while the China market is projected to reach USD 0.14 billion by 2026, and the India market is projected to reach USD 0.03 billion by 2026.

Latin America

The adult malignant glioma therapeutics market in Latin America is gradually expanding with improving access to oncology care and rising diagnosis rates, particularly in urban centers of Brazil and Mexico. Government initiatives to strengthen cancer care infrastructure and increasing availability of specialized treatment centers are expected to support market growth.

Middle East & Africa

The Middle East & Africa market growth is anticipated due to increasing awareness of malignant brain tumors and ongoing investments in advanced healthcare infrastructure, especially in countries such as Saudi Arabia, the UAE, and South Africa. Gradual improvements in diagnostic capabilities and access to specialized neuro-oncology services are expected to enhance treatment uptake over time.

Regional Analysis

"High Prevalence of Malignant Glioma and Huge Spending on Healthcare in North America are Contributing to the Dominance of the Region in The Global Adult Malignant Glioma Therapeutics Market"

Glioblastoma multiforme is a malignant astrocytoma and the most common primary brain tumor among adults. According to the American Society of Clinical Oncology (ASCO), about 17,000 new cases of high-grade gliomas, or HGG, are expected to be diagnosed in the U.S. in 2024. Rise in the incidence of the disease, strong economy, huge spending on the healthcare, high diagnosis rate owing to awareness about the healthcare among the population are predominant factors contributing the dominance of the region in the market trend.

Key Market Players 

"Merck & Co., Inc. and F. Hoffmann-La Roche Ltd to Account for Major Market Share in Terms of Revenue"

Temozolomide is the Merck & Co., Inc.’s leading product available in the U.S. as temodar and internationally as temodal. The company has a well-established footprint across the major markets. Moreover, its strategies to expand in the emerging economies are making the company leader in the glioma therapeutics. Roche dominates the adult malignant glioma therapeutic market with its leading product Avastin, approved for the treatment of malignant glioma due to strong clinical pieces of evidence supporting treatment merits.

KEY COMPANIES COVERED

• Merck & Co., Inc.
• Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Novocure
• Other Key Players

Key Industry Developments

• July 2021 - Basilea Pharmaceutica Ltd., announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to the company’s tumor checkpoint controller, lisavanbulin, for the treatment of patients suffering with malignant glioma.
• May 2021 - Novocure GmbH entered into a clinical trial collaboration with GT Medical Technologies, Inc., in order to develop Tumor Treating Fields (TTF) in combination with GT Medical’s GammaTile Surgically Targeted Radiation Therapy (STaRT) for treatment of recurrent glioblastoma.
• January 2020 - Pfizer Inc., introduced three new biosimilars i.e. Zirabev (Avastin), Ruxience (Rituxan) and Trazimera (Herceptin) at a discounted price in the U.S. market. Among these, Zirabev was approved for five types of cancer including recurrent glioblastoma.

Report Coverage

Glioma is a type of tumor that arises in the glial cells of the brain or spine. These comprise of around 30-40% of the primary central nervous system tumors and about 70-80% of all the malignant brain tumors. Unmet medical needs, increase in the global prevalence of the disease, and growing affordability for advanced therapies such as targeted therapies are likely to augment the demand for products designed for the treatment of adult malignant glioma.

The glioblastoma multiforme is the most common form of the glioma occurring in the adult population. It is the deadliest form of the disease requiring high end of medical care. Despite the continuous increase in the global patient population of glioma, the incidence is still less and the products approved for the treatment comes under the orphan category. The high cost of product development and less patient population are the major factors hindering the entry of new players in the market.

The adult malignant glioma therapeutics market report provides qualitative and quantitative insights on adult malignant glioma therapeutics and detailed analysis of market size and growth rate, growth opportunities for all possible segments in the market. The market is segmented by therapy, disease type, the end-user, and region. In terms of therapy, the market segmented into chemotherapy, radiation therapy, targeted therapy, and others.

In terms of disease type, the market is studied for segments such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others. Various end-users covered under the report are hospitals, specialty clinics, cancer and radiation therapy centers, others. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, and the rest of the World. The regions are further categorized into countries.

Along with this, the report provides elaborative analysis of the adult malignant glioma therapeutics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of glioma by key countries, an overview of technological advancements in the glioma therapy, recent industry developments such as mergers & acquisitions, and pipeline analysis.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation